Findings

What do systematic reviews say?

4 questions · 4 findings · 1 reviews · Hypertension

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 25%Moderate 3 · 75%High 0 · 0%

Myocardial infarction · patients with hypertension

CCBs showed no clear difference in myocardial infarction compared with ACE inhibitor (low certainty).

1 finding from 1 review

Calcium channel blockers versus other classes of drugs for hypertension 2022 · Cochrane Headline outcomes only
RR 1.05 [0.97, 1.14]
7 studies · 27999 participants
Low

Myocardial infarction · patients with hypertension

CCBs probably leads to lower myocardial infarction compared with ARB (moderate certainty).

1 finding from 1 review

Calcium channel blockers versus other classes of drugs for hypertension 2022 · Cochrane Headline outcomes only
RR 0.82 [0.72, 0.94]
6 studies · 25611 participants
Moderate

Myocardial infarction · patients with hypertension

CCBs showed no clear difference in myocardial infarction compared with diuretic (moderate certainty).

1 finding from 1 review

Calcium channel blockers versus other classes of drugs for hypertension 2022 · Cochrane Headline outcomes only
RR 1 [0.92, 1.08]
5 studies · 34072 participants
Moderate

Myocardial infarction · patients with hypertension

CCBs showed no clear difference in myocardial infarction compared with β‐blocker (moderate certainty).

1 finding from 1 review

Calcium channel blockers versus other classes of drugs for hypertension 2022 · Cochrane Headline outcomes only
RR 0.9 [0.79, 1.02]
3 studies · 22249 participants
Moderate